Nordicus Partners Corporation Acquires 95% Stake in Orocidin A/S
Beverly Hills, California., May 15, 2024 (GLOBE NEWSWIRE) — Nordicus Partners Corporation (OTCQB:NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. Life Sciences companies with optimal conditions to establish themselves on the U.S. market, announced today that it has entered into an agreement with Orocidin A/S (“Orocidin”) to acquire a 95% stake from eleven of Orocidin’s shareholders for $38,000,000. Nordicus will be issuing 38 million restricted common shares in an all-stock transaction to the selling shareholders.
Related news for (NORD)
- Nordicus Partners Corporation Announces Key Milestone in Development of Orocidin’s Breakthrough Treatment for Periodontitis
- Nordicus Partners To Host Investor Relations Webinar on July 10, 2024
- Orocidin – New Insights Into The Treatment Of Periodontitis
- Nordicus Partners Corporation Appoints Peter Severin as Chairman Of The Board of Directors
- Nordicus Partners Corporation Engages FORCE Family Office